The pre-seed round was backed by participants including Y Combinator and the UK government.
"The discovery of novel pharmaceuticals is one of our most important weapons in fighting disease. However, the drug development pipeline is often driven by trial-and-error and held up for many months during the identification of scalable manufacturing processes, delaying clinical trials. Our AI-powered models learn from historical data, cutting up to 95% of experimental work and accelerating these workflows by 30x."
The funding round was backed by the Midlands Engine Investment Fund, Mercia Ventures, and Pioneer Group.
"Our mission is to help companies avoid unnecessary animal testing and provide more accurate and relevant test results. This latest funding will enable us to continue building our range of tests and assays and use our model for different purposes, across different industries. We will also continue engaging with regulators to adapt industry standards tests to become animal free, and establish ImmuONE as a leading provider."
The funding will support the design, manufacturing, and field trials of a non-antibiotic treatment for Helicobacter pylori.
"I’m excited by the possibility for this treatment to help a lot of people, benefiting their overall health and avoiding the misery of side effects from antibiotics."
The seed round was co-led by Montage Ventures and AIX Ventures to fund asset expansion and clinical trials.
"We're thrilled to have the support of this leading investor syndicate in our mission to rescue promising yet struggling drugs with our technology. Traditional safety assessments reveal when something is wrong, but our platform goes a step further by identifying the exact molecular and biological issues to provide actionable insights to re-engineer and revive therapies. With this funding, we can expand our efforts to salvage distressed assets and accelerate the delivery of life-saving therapies to patients."
The financing round was co-led by Radical Ventures and Sofinnova Partners to accelerate the development of programmable biology tools.
"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."
